Brad Loncar specializes in investing in immuno-oncology related companies, and he’s been closely tracking the progress of the two big checkpoint drugs on the market from Bristol-Myers Squibb (Opdivo) and Merck (Keytruda).
Here’s his latest chart on how they’re doing in the market. “Both Opdivo and Keytruda are having great launches,” Loncar notes, “though Opdivo is clearly the winner by a wide margin because it does not require prior biomarker testing.”
Roche will be up soon with the first sales of its newly approved PD-L1 drug Tecentriq, with AstraZeneca and Pfizer looking for near-term entries.
Get Endpoints News in your inbox
Newsletters for those who discover, develop, and market drugs. Join 13,000+ biopharma pros who read Endpoints News every day. Free subscription.
Subscribe to Endpoints
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.